Cochrane · systematic review · CD006391
Benzodiazepines for schizophrenia
Dold, M, Li, C, Tardy, M, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
16
No studies
1
Included studies
NR
No studies 1 · 5.9%Ungraded 0 · 0%Very low 11 · 64.7%Low 5 · 29.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
BENZODIAZEPINES AS SOLE TREATMENT versus PLACEBO AS SOLE TREATMENT for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No clinically important response to treatment ‐ short term BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO | RR 0.67 [0.44, 1.02] | 6 studies · 382 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Leaving the study early due to any reason (overall acceptability of treatment) BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO | RR 0.89 [0.57, 1.38] | 8 studies · 440 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early due to adverse effects (overall tolerability of treatment) BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO | no estimate extracted | 4 studies · 161 participants | Very low Downgraded: risk of bias, imprecision |
Number of participants tranquillised at endpoint of the study (Desired sedation/tranquillisation) BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO | no estimate extracted | NR | No studies |
BENZODIAZEPINES versus ANTIPSYCHOTICS for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No clinically important response to treatment ‐ ultra short term (at 60 minutes) BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 0.61 [0.2, 1.86] | 1 study · 44 participants | Very low Downgraded: risk of bias, imprecision |
No clinically important response to treatment ‐ ultra short term (at 12 hours) BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 0.75 [0.44, 1.3] | 1 study · 66 participants | Low Downgraded: imprecision |
No clinically important response to treatment ‐ short term BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 1.48 [0.64, 3.46] | 2 studies · 112 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early due to any reason (overall acceptability of treatment) BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 0.73 [0.45, 1.18] | 13 studies · 738 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early due to adverse effects (overall tolerability of treatment) BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 13 [0.78, 216.39] | 5 studies · 444 participants | Very low Downgraded: risk of bias, imprecision |
Desired sedation ‐ ultra short term ‐ asleep at 12 hours BENZODIAZEPINES vs ANTIPSYCHOTICS | RR 0.75 [0.44, 1.3] | 1 study · 66 participants | Low Downgraded: imprecision |
ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS for schizophrenia
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
No clinically important response to treatment ‐ ultra short term (at 60 minutes) ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 0.07 [0, 1.13] | 1 study · 45 participants | Very low Downgraded: risk of bias, imprecision |
No clinically important response to treatment ‐ ultra short term (at 12 hours) ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 0.85 [0.51, 1.41] | 1 study · 67 participants | Low Downgraded: imprecision |
No clinically important response to treatment ‐ short term (3 weeks or longer) ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 0.87 [0.49, 1.54] | 6 studies · 511 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early due to any reason (overall acceptability of treatment) ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 1.36 [0.81, 2.3] | 19 studies · 1185 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early due to adverse effects (overall tolerability of treatment) ‐ short term ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 3.24 [0.68, 15.45] | 6 studies · 415 participants | Very low Downgraded: risk of bias, imprecision |
Desired sedation ‐ ultra short term ‐ tranquillised at 60 minutes ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 1.39 [1.06, 1.83] | 1 study · 45 participants | Low Downgraded: risk of bias |
Desired sedation ‐ ultra short term ‐ asleep at 12 hours ADJUNCTIVE BENZODIAZEPINES + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS | RR 0.85 [0.51, 1.41] | 1 study · 67 participants | Low Downgraded: imprecision |